| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/10/2004 | WO2003053169A8 Soft drink replacer |
| 09/10/2004 | WO2003003979A3 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 09/10/2004 | WO2002098890A3 MARKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 09/10/2004 | WO2002097053A3 Small molecule antagonists of bcl2 family proteins |
| 09/10/2004 | WO2002064085A3 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 09/10/2004 | CA2517290A1 Muscle-building agent and preventive or remedy for muscle weakening |
| 09/10/2004 | CA2517007A1 Therapeutic malonic acid/acetic acid c60 tri-adducts of buckminsterfullerene and methods related thereto |
| 09/10/2004 | CA2516824A1 Pyrazolo[1,5-a]pyrimidine derivatives |
| 09/10/2004 | CA2516407A1 Heteroarylcarbamoylbenzene derivatives |
| 09/10/2004 | CA2515975A1 Peptide derivatives having .beta.-secretase inhibitory activity |
| 09/09/2004 | US20040176625 Kinesin motor modulators derived from the marine sponge Adocia |
| 09/09/2004 | US20040176601 Benzimisazo[4,5-f]isoquinolinone derivatives |
| 09/09/2004 | US20040176595 Glucocorticoid receptor modulators |
| 09/09/2004 | US20040176570 Intermediates and enzymes of the non-mevalonate isoprenoid pathway |
| 09/09/2004 | US20040176462 NPY Y5 antagonist |
| 09/09/2004 | US20040176461 Sulfonyl-amino or carbonyl-amino derivatives; osteoporosis bone disorders; therapeutic drug or kits including anti-resorptive agents, anabolic agents; |
| 09/09/2004 | US20040176448 Use of carnitine and/or one or more acyl-carnitines for producing cosmetic or dermatological preparations, which increase ceramide biosynthesis |
| 09/09/2004 | US20040176446 Substituted amino dicarboxylic acid derivatives |
| 09/09/2004 | US20040176443 Capsaicin receptor ligands |
| 09/09/2004 | US20040176438 Novel mono- and di-fluorinated beozothiepine copmunds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
| 09/09/2004 | US20040176433 treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis |
| 09/09/2004 | US20040176428 treatment of Type 2 diabetes mellitus, obesity and lipid disorders; coadministration with HMG CoA reductase inhibitors |
| 09/09/2004 | US20040176422 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 09/09/2004 | US20040176421 such as 1,4-Bis-{N-[3-(3-aminomethylphenylproplonyl)-2-methoxycarbonylpyrrolidin-4-yl]aminocarbonyloxy}-2-butyne dihydrochloride; for treatment of asthma, allergic conjunctivitis, allergic rhinitis, psoriasis, and ulcerative colitis |
| 09/09/2004 | US20040176419 particularly chronic obstructive pulmonary disease (COPD), asthma or a related pulmonary disease such as chronic bronchitis or allergic rhinitis |
| 09/09/2004 | US20040176418 protease activated receptor (PAR) antagonists will be useful in the treatment of thrombotic, inflammatory, atherosclerotic and fibroproliferative disorders |
| 09/09/2004 | US20040176417 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands |
| 09/09/2004 | US20040176414 principle metabolite of cisapride; has both 5-HT3 antagonistic and 5-HT4 agonistic; devoid of central nervous system effects; separating racemic mixture by liquid chromatography over a chiral stationary phase |
| 09/09/2004 | US20040176411 especially useful for treating asthma and/or rhinitis; example compound N-[[[2-[4-(3,4-dichlorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-4-methyl-benzenesulfonamide |
| 09/09/2004 | US20040176407 Novel isoxazolopyridone derivatives and their use |
| 09/09/2004 | US20040176400 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| 09/09/2004 | US20040176397 (Oxo-Pyrazolo[1,5a]pyrimidin-2-yl)Alkyl-Carboxamides |
| 09/09/2004 | US20040176389 Piperazine oxime dervatives having nk-1 receptor antagonistic activity |
| 09/09/2004 | US20040176388 example compound: cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indole; treatment of CNS and other disorders |
| 09/09/2004 | US20040176386 Compounds |
| 09/09/2004 | US20040176384 inhibit Tissue factor expression and vascular permeability factor expression in cancer cells and in vascular endothelial cells in the tumor microenvironment; low toxicity to normal vascular endothelial cells |
| 09/09/2004 | US20040176379 agonist effect from one or more of a somatostatin subtype receptor; diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X; inhibiting the proliferation of helicobacter pylori |
| 09/09/2004 | US20040176365 1,8-Naphthyridin-2(1H)-one derivatives; antiasthmatic, antihistamine, and bronchodilator agents; nontoxic, side effect reduction |
| 09/09/2004 | US20040176363 N-Acylpiperazine derivatives; cardiovascular disorders; anticoagulants |
| 09/09/2004 | US20040176361 2H-Isoquinolin-1-one derivatives as poly/ADP-ribose/ polymerase inhibitors |
| 09/09/2004 | US20040176353 Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| 09/09/2004 | US20040176347 Synergistic mixture of astrocyte function-improving agent and tissue plasminogen activator thrombolytic agent |
| 09/09/2004 | US20040176329 Treating Alzheimer*s, Parkinson*s, and Binswanger*s disease; antiischemic agents, dementia; nervous system, brain and neurodegenerative disorders |
| 09/09/2004 | US20040176327 Use of bisphosphonic acids for treating angiogenesis |
| 09/09/2004 | US20040176326 N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof |
| 09/09/2004 | US20040176324 Derivatives of 4,7-ethanothiopyrano[3,4-c]pyrrole-1,3-(2H)-dione, 4,7-epoxy-1H-isoindole-1,3(2H)-dione, and/or 4,7-ethano-1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives; autoimmune diseases; anticarcinogenic agents |
| 09/09/2004 | US20040176320 Use of at least one glycoinhibitor substance |
| 09/09/2004 | US20040176309 Siglec inhibitors |
| 09/09/2004 | US20040176308 Sodium dependent glucose transporter 1 inhibitors; blocking small intestine absorption of glucose; diabetes |
| 09/09/2004 | US20040176302 Methods for inhibiting tumor cell proliferation |
| 09/09/2004 | US20040176297 Characterizing and predicting responses; identifying most efficient, cost effective and/or convenient treatment regimens; computer profiling |
| 09/09/2004 | US20040176288 Treatment and composition for wound healing |
| 09/09/2004 | US20040176287 Employing such as follistatin to increase differentiation of stromal stem cells, myoblast and undifferentiated stromal cells to osteoblast cells |
| 09/09/2004 | US20040176285 Tip39 polypeptides |
| 09/09/2004 | US20040176284 1,2-Dithio-5,8,11,14,17-pentaazocycloeicosane derivatives |
| 09/09/2004 | US20040176279 Flint glycoforms |
| 09/09/2004 | US20040176252 Well tolerated; intracellularly increasing cAMP; antiasthmatics, antiinflammatories: regulation of eosinophiles activation and degranulation |
| 09/09/2004 | US20040175825 for drug screening/diagnostics for inflammation, arthritis and cancer; genetic engineering; kits |
| 09/09/2004 | US20040175791 DcR3 polypeptide, a TNFR homolog |
| 09/09/2004 | US20040175767 for lightening or darkening the pigmentation of cells and tissue (skin) in cells/cell-free systems; for drug screening |
| 09/09/2004 | US20040175766 Human pyrimidine receptor |
| 09/09/2004 | US20040175748 Using alterations in cyclin dependent kinase activity to identify modulators which inhibit or potentiate cellular senescence; antiaging/anticancer agents; enzyme inhibitors |
| 09/09/2004 | US20040175740 Using proopiomelanocortin animal mutant to identify modulators of weight and pancreatic disorders |
| 09/09/2004 | US20040175730 Comprises nucleotide sequences coding polypeptide associated with vascular permeability or proliferation of endothelial cells for treating intestinal malabsorption syndrome |
| 09/09/2004 | US20040175703 to be administered by inhalation, infusion, injection, or orally relates to double-stranded ribonucleic acid (dsRNA), and its use in mediating RNA interference in vitro and in vivo; genetic engineering |
| 09/09/2004 | US20040175439 method for increasing the levels of non-proeteinaceous extracellular protease inhibitors in plants comprising he step of stressing the plant prior to forming a plant extract |
| 09/09/2004 | US20040175437 preventing and treating certain inflammatory diseases, degenerative diseases and viral diseases in mammals |
| 09/09/2004 | US20040175420 at least one non-ionic or zwitterionic surfactant and dispersant; improves the efficacy and/or potency of the lipase inhibitor; inter-subject variability in efficacy and/or potency is reduced, as well as the frequency and intensity of side effects |
| 09/09/2004 | US20040175396 Prophylactic agent for enhancement of nerve growth factor production for treatment or prevention comprising an aqueous mushroom extract; neurodegenerative diseases, Alzheimer*s disease, and nervous system disorders; foods, beverages, feeds |
| 09/09/2004 | US20040175378 Monoclonal antibody 3G4, or an antigen-binding region or immunoconjugate thereof, produced by hybridoma ATCC PTA 4545; binds to phosphatidyl serine |
| 09/09/2004 | US20040175375 Downregulation of c-myc by promoting the ubiquitination of FBP, by administering an isolated p38/JTV-1protein or fragment or an isolated nucleic acid encoding said protein; |
| 09/09/2004 | US20040175363 Defective recombinant adenovirus; treatment of neurodenerative, cardiovascular, brain, genetic, nervous system and respiratory system disorders; Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS), atherosclerosis, and/or trisomy 2; adult respiratory distress syndrome; anticarcinogenic agents |
| 09/09/2004 | US20040175358 Side effect reduction using oxidized glutathione GSSG-reductase and glutathione peroxidase; reduced toxicity during chemotherapy |
| 09/09/2004 | US20040175348 formed by spray-drying a solution of an edible organic acid wherein chitosan is dissolved; storage stability |
| 09/09/2004 | US20040175342 Process of making and using composition containing oxidation-sensitive hydrophilic active principle and maleic anhydride copolymer |
| 09/09/2004 | DE10004790B4 Method for producing sewn or embroidered three-dimensional textile structure utilized for e.g. table cloth, involves connecting points on lattice structure with threads to form thread arrangement under which lattice structure is not visible |
| 09/08/2004 | EP1455190A1 Modulation of the activity of nuclear receptors via EWS |
| 09/08/2004 | EP1455186A1 Screening method |
| 09/08/2004 | EP1454917A2 Diabody-type bispecific antibody |
| 09/08/2004 | EP1454907A1 Quninazoline and pyridopyrmidine derivatives |
| 09/08/2004 | EP1454902A1 N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia |
| 09/08/2004 | EP1454898A1 Novel phenylalanine derivative |
| 09/08/2004 | EP1454897A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY |
| 09/08/2004 | EP1454629A2 Insulinotrophic agent based on preproglucagon |
| 09/08/2004 | EP1454628A2 Medical use of p38/JTV-1 |
| 09/08/2004 | EP1454626A1 Method of inducing apoptosis and compositions therefor |
| 09/08/2004 | EP1454145A2 Method for the assessment and prognosis of sarcoidosis |
| 09/08/2004 | EP1454142A2 Inhibition of tristetraproline for protection of the heart from cardiac injuries |
| 09/08/2004 | EP1454140A2 Diagnosis and treatment of atherosclerosis |
| 09/08/2004 | EP1454136A2 Methods and means for influencing intracellular communication and intracellular organelle transport |
| 09/08/2004 | EP1453962A2 Inhibitor oligonucleotides and their use for specific repression of a gene |
| 09/08/2004 | EP1453949A2 Production of cell suspensions |
| 09/08/2004 | EP1453909A1 Cereal beta glucan compositions, methods of preparation and uses thereof |
| 09/08/2004 | EP1453852A2 Selective urokinase inhibitors |
| 09/08/2004 | EP1453845A2 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 09/08/2004 | EP1453840A1 Phosphonates useful as modulators of t-gamma-9-delta-2 lymphocyte activity |
| 09/08/2004 | EP1453837A2 Targeted therapeutics and uses thereof |
| 09/08/2004 | EP1453835A2 Adenosine a 2a receptor antagonists |
| 09/08/2004 | EP1453832A1 Ring fused pyrazole derivatives |
| 09/08/2004 | EP1453829A1 Sulfonamido substituted imidazopyridines |